Estrella Immunopharma, Inc. (ESLA)
USD 1.13
(-8.13%)
USD 1.13
(-8.13%)
| Breakdown | 2024 | 2022 | 2022 | 2021 |
|---|---|---|---|---|
| Revenue | - | - | - | - |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 7.31 Million | 1.56 Million | 1.68 Million | 733.69 Thousand |
| Selling, General and Administrative Expenses | 3.2 Million | 1.36 Million | 296.24 Thousand | 276.46 Thousand |
| Research and Development Expenses | 4.1 Million | - | 1.38 Million | 457.23 Thousand |
| Other Expenses | - | -201.31 Thousand | -70.15 Thousand | - |
| Cost and Expenses | 7.31 Million | 1.56 Million | 1.68 Million | 733.69 Thousand |
| Operating Income | -7.31 Million | -1.56 Million | -1.68 Million | -733.69 Thousand |
| Interest Expense | - | - | - | - |
| Income Tax Expense | 1625.00 | 80.64 Thousand | -235.13 Thousand | -206.29 Thousand |
| Earnings before Tax | -7.31 Million | -915.45 Thousand | -1.68 Million | -733.69 Thousand |
| Net Income | -7.31 Million | -996.1 Thousand | -1.68 Million | -733.69 Thousand |
| Earnings Per Share Basic | -0.21 | -0.17 | -0.29 | -0.02 |
| Earnings Per Share Diluted | -0.21 | -0.17 | -0.29 | -0.02 |
| Weighted Average Shares Outstanding | 35.2 Million | 5.76 Million | 5.84 Million | 35.2 Million |
| Weighted Average Shares Outstanding (Diluted) | 35.2 Million | 5.76 Million | 5.84 Million | 35.2 Million |
| Gross Margin | - | - | - | - |
| EBIT Margin | - | - | - | - |
| Profit Margin | - | - | - | - |
| EBITDA | -7.31 Million | -915.45 Thousand | -247.71 Thousand | -733.69 Thousand |
| Earnings Before Tax Margin | - | - | - | - |
| Breakdown | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | 3.94 Million | 469.53 Thousand | 1.02 Million | 1.87 Million | 169.23 Thousand | 149.65 Thousand |
| Selling, General and Administrative Expenses | 424.44 Thousand | 444.53 Thousand | 945.16 Thousand | 1.38 Million | 155.29 Thousand | 136.55 Thousand |
| Research and Development Expenses | 3.52 Million | 25 Thousand | 75.45 Thousand | 483.46 Thousand | - | 2.62 Million |
| Other Expenses | - | - | - | - | -13.94 Thousand | -13.1 Thousand |
| Cost and Expenses | 3.94 Million | 469.53 Thousand | 1.02 Million | 1.87 Million | 169.23 Thousand | 149.65 Thousand |
| Operating Income | -3.94 Million | -469.53 Thousand | -1.02 Million | -1.87 Million | -169.24 Thousand | -149.65 Thousand |
| Interest Expense | - | - | - | - | - | - |
| Income Tax Expense | 1625.00 | 39.58 Thousand | -122.08 Thousand | -41.58 Thousand | 21.07 Thousand | 19.46 Thousand |
| Earnings before Tax | -3.94 Million | -469.53 Thousand | -1.02 Million | -1.87 Million | -54.92 Thousand | -43.86 Thousand |
| Net Income | -3.95 Million | -469.53 Thousand | -1.02 Million | -1.87 Million | -76 Thousand | -63.32 Thousand |
| Earnings Per Share Basic | -0.11 | -0.01 | -0.03 | -1.78 | -0.03 | -0.03 |
| Earnings Per Share Diluted | -0.11 | -0.01 | -0.03 | -1.78 | -0.03 | -0.03 |
| Weighted Average Shares Outstanding | 35.51 Million | 35.51 Million | 35.2 Million | 1.05 Million | 2.32 Million | 2.32 Million |
| Weighted Average Shares Outstanding (Diluted) | 35.51 Million | 35.51 Million | 35.2 Million | 1.05 Million | 2.32 Million | 2.32 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | -3.94 Million | -469.53 Thousand | -1.02 Million | -1.87 Million | -169.24 Thousand | -149.65 Thousand |
| Earnings Before Tax Margin | - | - | - | - | - | - |
CNNC
CBOX
600993
DQJCY
000930
HEN